Search

Displaying results 1131 - 1140 of 4359 in total
  1. Drug

    Pramlintide

    go.drugbank.com/drugs/DB01278
    ApprovedInvestigational

    It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.

  2. Drug

    Methylcellulose

    go.drugbank.com/drugs/DB11228
    ApprovedInvestigational

    Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. … It is available under a variety of trade names as a treatment for constipation. Like cellulose, it is not digestible, not toxic, and not allergenic

  3. Drug

    Dextran

    go.drugbank.com/drugs/DB09255
    ApprovedInvestigationalVet approved

    When labelled with technetium Tc99m, dextran 75 is intravenously administered as an imaging agent to detect and diagnose conditions in the vascular compartment such as pericardial effusion or ventricular

  4. Drug

    Iodixanol

    go.drugbank.com/drugs/DB01249
    Approved

    Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the

  5. Drug

    Oliceridine

    go.drugbank.com/drugs/DB14881
    ApprovedInvestigational

    [A218031, A218046] However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors such as those involving β-arrestin … effects such as constipation and respiratory depression.

  6. Drug

    Magnesium citrate

    go.drugbank.com/drugs/DB11110
    ApprovedInvestigational

    [L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.

  7. Drug

    Fenofibric acid

    go.drugbank.com/drugs/DB13873
    ApprovedInvestigational

    [A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed

  8. Drug

    Fexofenadine

    go.drugbank.com/drugs/DB00950
    ApprovedInvestigational

    [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. … for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation antihistamines, such as

    Products: FEXOFENADINA MYLAN GENERICS
  9. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin

  10. Drug

    Cimetidine

    go.drugbank.com/drugs/DB00501
    ApprovedInvestigational

    It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.